Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including reports of deaths and hospitalizations, while working with the FDA to resolve issues.
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
